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EDITORIAL COVID-19 and 
cardiovascular disease
The most common symptoms of COVID-19 are fever, breath-
lessness, fatigue and dry cough. Some patients may have 
muscular aches and pains, nasal congestion, runny nose, sore 
throat or diarrhoea. Symptoms are usually mild and begin 
gradually. Many people become infected but remain asymp-
tomatic. Over 80% will recover from the disease without 
needing special treatment. Around 1 out of every 6 people 
who gets COVID-19 becomes seriously ill and develops 
difficulty breathing. Older people, and those with underlying 
medical problems like high blood pressure, cardiovascular 
disease (CVD), lung disease, cancer or diabetes, are more likely 
to develop serious illness. 
COVID-19 is transmitted from those who have been infected 
by SARS-CoV-2. The disease can spread from person to person 
through small droplets from the nose or mouth, which are 
spread when a person with COVID-19 coughs or exhales. 
These droplets land on objects and surfaces around the per-
son. The virus may remain viable on hard surfaces for days. 
Other people then catch COVID-19 by touching these objects 
or surfaces, then touching their eyes, nose or mouth. Individuals INTRODUCTION
In December 2019, a cluster of patients with pneumonia of 
unknown cause was linked to a seafood wholesale market in 
Wuhan, China. A previously unknown betacoronavirus was 
discovered through unbiased sequencing in samples from 
patients with pneumonia. Human airway epithelial cells were 
used to isolate a novel coronavirus, named severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019-
nCoV for short (Figure 1). SARS-CoV-2 formed a clade within 
the subgenus sarbecovirus, subfamily Orthocoronavirinae. Dif-
ferent from both MERS-CoV and SARS-CoV, 2019-nCoV is 
the seventh member of the family of coronaviruses that infect 
humans. Coronavirus disease (COVID-19) is the clinical 
infectious disease syndrome caused by SARS-CoV-2.(1) SARS-
CoV-2 infects host cells through the angiotensin-converting 
enzyme type 2 (ACE2) receptors, leading to COVID-19-related 
pneumonia and multiorgan dysfunction, while also causing 
acute myocardial injury and chronic damage to the cardiovas-
cular system. 
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FIGURE 1: Illustration of 2019-nCoV.













also catch COVID-19 if they breathe in droplets from a per-
son with COVID-19 who coughs out or exhales droplets. 
Hence the primacy of physical distancing as a fundamental 
public health concept: staying more than 1.5 metres away from 
a person who is sick to prevent transmission. The incubation 
period refers to the time between catching the virus and 
beginning to have symptoms of the disease. Most estimates of 
the incubation period for COVID-19 range from 1 - 14 days, 
but most commonly it is around 5 days. Asymptomatic indi-
viduals are still capable of transmitting the virus.
The primary pathology of COVID-19 is acute respiratory dis-
tress syndrome (ARDS), characterised by diffuse alveolar 
damage (e.g. including hyaline membranes). Pneumocytes with 
viral cytopathic effect are seen, implying direct virus damage 
rather than a purely hyper-inflammatory injury. Emerging evi-
dence suggests that some patients may respond to COVID-19 
with an exuberant “cytokine storm” reaction, with features of 
bacterial sepsis or haemophagocytic lymphohistiocytosis. 
Clinical markers of this cytokine storm include elevations of 
C-reactive protein, interleukin-6 and ferritin, which appear to 
track with disease severity and mortality.
Pathophysiologically, there are different stages of COVID-
19: (i) an initial replicative phase, occurring over a period of 
several days characterised by an innate immune response and 
relatively mild symptoms due to direct viral cytopathic effect 
and innate immune responses; and (ii) an adaptive immunity 
stage characterised by falling viral titres and increased inflam-
matory cytokines, which lead to tissue damage, causing clinical 
deterioration. Disease progression may explain the clinical 
phenomenon where patients have mild symptoms for a few 
days, and then suddenly deteriorate when they enter the 
adaptive immunity stage.
Epidemiologically, disease spread in the population occurs in 3 
phases: (i) stage 1 with only imported cases; (ii) stage 2 with 
limited community transmission; and (iii) stage 3 with wide-
spread community transmission. Evidence-based public health 
interventions that reduce disease transmission include hand 
hygiene and social distancing.
COVID-19 AND CARDIOVASCULAR DISEASE
Although the clinical manifestations of COVID-19 are pre-
dominantly respiratory, some patients may have clinical 
evidence of cardiovascular injury.(2) Further, patients with 
cardiovascular disease (CVD) have an increased risk of severe 
presentations and increased mortality. Hence, understanding 
the damage caused by SARS-CoV-2 to the cardiovascular 
system is of importance.
SARS-CoV-2 and ACE2
ACE2 is a membrane-bound aminopeptidase important for 
the cardiovascular and immune systems.(3) ACE2 plays an 
important role in regulation of cardiovascular function, cardio-
vascular remodelling and genesis of hypertension and dia-
betes, and is highly expressed in the heart and lungs. ACE2 
is the functional receptor for coronaviruses including SARS-
CoV and SARS-CoV-2. Through binding the ACE2 receptor, 
SARS-CoV-2 mainly invades alveolar epithelial cells, resulting 
in respiratory symptoms, which are more severe in patients 
with CVD, likely due to increased secretion of ACE2 in these 
patients. Furthermore, ACE2 levels can be increased using 
renin–angiotensin–aldosterone system inhibitors. Given that 
ACE2 is a functional  receptor for SARS-CoV-2, the safety 
and potential effects of antihypertension therapy with ACE 
inhibitors or angiotensin-receptor blockers in patients with 
COVID-19 have been considered and, to date, there has 
been no signal that use of ACE inhibitors, angiotensin receptor 
blockers and mineralocorticoid receptor antagonists are asso-
ciated with adverse outcomes in COVID-19 patients. 
SARS-CoV-2 and acute myocardial injury
Myocarditis and myocardial injury associated with the SARS-
CoV-2 occurred in 5 of the first 41  patients diagnosed with 
COVID-19 in Wuhan, which mainly manifested as an increase 
in high-sensitivity cardiac troponin I levels.(4) Eighty percent of 
patients with myocardial injury were admitted  to the inten-
sive-care unit (ICU), which indicates the serious nature of 
the myocardial injury in patients with COVID-19. Blood 
pressure levels were significantly  higher in patients treated in 
the ICU than in those not treated in the ICU.(4) In a different 
report, levels of biomarkers of myocardial injury were signi-
ficantly higher in patients treated in the ICU than in those not 
treated in the ICU,(5) suggesting that patients with severe 
symptoms often have complications involving acute myo-
cardial injury. Among the confirmed cases of SARS-CoV-2 
infection reported by the National Health Commission of 
China, some of the patients first went to see a doctor because 
of cardiovascular symptoms. The patients presented with heart 
palpitations and chest tightness rather than with respiratory 
symptoms, such as fever and cough, but were later diagnosed 
with COVID-19. In patients with COVID-19, the incidence of 
cardiovascular symptoms is high, owing to the systemic inflam-
matory response and immune system disorders during disease 
progression. The mechanism of acute myocardial injury caused 
by SARS-CoV-2 infection might be related to ACE2-related 
signalling pathways, the cytokine storm triggered by an imbal-
anced response by type 1 and type 2 T helper cells, and respi-
ratory dysfunction and hypoxaemia caused by COVID-19.
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drastically affected by school closures, social distancing policies, 
and disruption in the availability of food and other essentials.
Sonographers, nurses, technicians, radiographers and physicians 
have a duty to care for patients and are at the frontlines in 
the battle against disease. We are at high risk, particularly when 
we participate in the care of patients who are suspected or 
confirmed to have highly contagious diseases. While dedication 
to patient care is at the heart of our profession, we also have a 
duty to care for ourselves and our loved ones and to protect 
all our patients by preventing the spread of disease. This means 
reducing our own risk while practicing judicious use of 
PPE. Cardiology staff who undertake procedures that increase 
the risk of transmission, including echocardiography, cardiac 
catheterisation and cardiopulmonary resuscitation (including 
endotracheal intubation) need to take precautions to protect 
themselves from the risk of COVID-19. Echocardiographic 
services should not be ordered if they are unlikely to provide 
clinical benefit. Repeat echocardiograms should not be 
performed unless there has been a clear change in clinical 
status. The portability of echocardiography affords a clear 
advantage in imaging patients without having to move them 
and risk virus transmission in the clinic or hospital. In addi-
tion, staff should be vaccinated against influenza, as the flu 
season has been particularly devastating in the northern 
hemisphere this year.
Healthcare systems globally could be operating at more than 
maximum capacity for many months. Healthcare workers, 
unlike ventilators or wards, cannot be urgently manufactured 
or run at 100% capacity or occupancy for long periods. It is 
vital that governments see workers not simply as pawns to be 
deployed, but as human individuals. In the global response, 
the safety of healthcare workers must be ensured. Adequate 
provision of PPE is just the first step; other practical measures 
must be considered, including cancelling non-essential services 
to prioritise resources; provision of food, rest, and family sup-
port; and psychological support. Presently, healthcare workers 
are every country's most valuable resource.
CONCLUSION
SARS-CoV-2 is a new virus that infects host cells through ACE2 
to cause COVID-19, while also causing damage to the myo-
cardium. Patients with underlying CVD and SARS-CoV-2 
infection have an adverse prognosis. Therefore, attention 
should be given to cardiovascular protection during treat-
ment for COVID-19. Cardiovascular staff are at a particularly 
increased risk and need to take important precautionary 
measures to reduce infection. 
SARS-CoV-2 and chronic cardiac injury
Given that SARS-CoV-2 has a similar structure to SARS-
CoV, this novel virus might also cause chronic damage to the 
cardiovascular system, and attention should be given to 
cardiovascular protection during treatment for COVID-19. 
A 12-year follow-up survey of 25 patients who recovered 
from SARS-CoV infection found that 68% had hyperlipi-
daemia, 44% had cardiovascular system abnormalities and 60% 
had glucose metabolism disorders.(6) COVID-19 is also asso-
ciated with a hypercoagulable state and increased risk of deep 
vein thrombosis and pulmonary embolism.
SARS-CoV-2 and pre-existing 
cardiovascular disease
Elderly people with comorbidities are more likely to be infected 
with SARS-CoV-2, especially those with hypertension, coronary 
heart disease or diabetes. Furthermore, patients with CVD are 
more likely to develop severe symptoms if infected with 
SARS-CoV-2. Therefore, patients with CVD account for a large 
proportion of deaths from COVID-19. For patients with severe 
symptoms of COVID-19, 58% had hypertension, 25% had 
heart disease and 44% had arrhythmia.(6) Thirty-five percent of 
patients with SARS-CoV-2 infection had a history of hyper-
tension and 17% had a history of coronary heart disease. 
Patients with acute coronary syndrome (ACS) who are infected 
with SARS-CoV-2 often have a poor prognosis. In patients 
with ACS, cardiac functional reserve can be reduced owing to 
myocardial ischaemia or necrosis. Drug-related heart damage 
during COVID-19 treatment is a concern. In particular, the 
use of antiviral drugs should be monitored. Many antiviral 
drugs can cause cardiac insuff iciency, arrhythmia or other 
cardiovascular disorders; therefore, during treatment of 
COVID-19, especially with the use of antivirals, the risk of 
cardiac toxicity must be closely monitored.(7)
COVID-19 AND CARDIOVASCULAR 
HEALTHCARE WORKERS
Worldwide, as millions of people stay at home to minimise 
transmission of SARS-CoV-2, healthcare workers prepare to 
do the exact opposite. As the pandemic accelerates, access 
to personal protective equipment (PPE) for health workers is 
a key concern. Medical staff are prioritised in many countries, 
but PPE shortages have been described in the most affected 
facilities. Some medical staff are waiting for equipment while 
already seeing patients who may be infected or are supplied 
with equipment that might not meet requirements. Alongside 
concerns for their personal safety, healthcare workers are 
anxious about passing the infection to their families. Healthcare 
workers who care for elderly parents or young children will be 
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